OCUMENSION THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.47 HKD | +7.83% |
|
+8.92% | -3.14% |
| 04-15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| 04-15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
| Sales 2023 | 246M 34M 266M 46.48M | Sales 2024 * | 444M 61.22M 479M 83.69M | Capitalization | 4.15B 573M 4.49B 784M |
|---|---|---|---|---|---|
| Net income 2023 | -380M -52.44M -411M -71.69M | Net income 2024 * | -251M -34.64M -271M -47.36M | EV / Sales 2023 | 17 x |
| Net cash position 2023 * | 962M 133M 1.04B 181M | Net cash position 2024 * | 937M 129M 1.01B 177M | EV / Sales 2024 * | 7.25 x |
| P/E ratio 2023 |
-10.3
x | P/E ratio 2024 * |
-16.6
x | Employees | 444 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 47.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +7.83% | ||
| 1 week | +8.92% | ||
| Current month | +11.94% | ||
| 1 month | +12.91% | ||
| 3 months | +24.42% | ||
| 6 months | -15.09% | ||
| Current year | -3.14% |
1 week
5.80
6.47
1 month
5.166.47
Current year
4.516.78
1 year
4.5110.40
3 years
4.5132.05
5 years
4.5143.00
10 years
4.5143.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 23-01-11 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 18-03-31 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 19-06-17 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 20-06-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.59% | 4 M€ | -27.92% | ||
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.47 | +7.83% | 1,504,500 |
| 24-04-25 | 6 | -0.50% | 1,037,500 |
| 24-04-24 | 6.03 | +1.17% | 976,000 |
| 24-04-23 | 5.96 | +2.05% | 232,000 |
| 24-04-22 | 5.84 | -1.68% | 534,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.989
CNY
Average target price
7.77
CNY
Spread / Average Target
+29.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.14% | 573M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 1477 Stock
